Literature DB >> 17374324

[Role of biological markers in inflammatory bowel disease].

Javier P Gisbert1, Yago González-Lama, José Maté.   

Abstract

The role played by the distinct biological markers in chronic inflammatory bowel disease (IBD) remains insufficiently characterized. C-reactive protein (CRP) has a short half-life and consequently it is elevated early after the onset of the inflammatory process and rapidly decreases after its resolution, making it an attractive marker of disease activity. Moreover, this test is inexpensive and easy to perform and is unaffected by medication. While Crohn's disease is associated with a marked CRP response, there is little or no elevation in the synthesis of this protein in ulcerative colitis. Erythrocyte sedimentation rate provides some advantages such as its ease of determination, availability, and reduced cost. Nevertheless, it also has several disadvantages, notably the fact that its concentration depends on age, the presence of anemia, smoking, and the use of certain drugs. Moreover, its utility is limited by its long half life and consequent prolonged latency period after changes in chronic IBD activity. In theory, fecal markers have the advantages of showing greater specificity in the diagnosis of chronic IBD. Several gastrointestinal diseases, including chronic IBD, show greater leukocyte elimination in feces and a close correlation has been described between fecal calprotectin concentration and leukocyte excretion quantified by 111indium. Advantages of this fecal marker are that it can be detected through a simple and inexpensive technique and also shows excellent stability in feces for prolonged periods. Like calprotectin, fecal lactoferrin is also quantified by a simple and inexpensive ELISA method, although there is considerably less experience with this latter marker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374324     DOI: 10.1157/13100073

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  6 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

2.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

3.  B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.

Authors:  Peipei Zhang; Xiaojing Liu; Aili Guo; Jing Xiong; Yu Fu; Kaifang Zou
Journal:  Dig Dis Sci       Date:  2016-04-07       Impact factor: 3.199

Review 4.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 5.  Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?

Authors:  Jong-Min Park; Na Young Han; Young-Min Han; Mi Kyung Chung; Hoo Keun Lee; Kwang Hyun Ko; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab.

Authors:  Fernando Magro; Susana Lopes; Marco Silva; Rosa Coelho; Francisco Portela; Diogo Branquinho; Luís Correia; Samuel Fernandes; Marília Cravo; Paulo Caldeira; Helena Tavares de Sousa; Marta Patita; Paula Lago; Jaime Ramos; Joana Afonso; Isabel Redondo; Patrícia Machado; George Philip; Joanne Lopes; Fátima Carneiro
Journal:  Therap Adv Gastroenterol       Date:  2019-08-30       Impact factor: 4.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.